Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies.
about
Modelling clinical systemic lupus erythematosus: similarities, differences and success storiesEvaluation of WO2014075392 and WO2014075393, Merck's first PI3Kδ inhibitor filings.PI3K inhibitors in inflammation, autoimmunity and cancer.Microbial production of novel sulphated alkaloids for drug discovery.
P2860
Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Characterization of Novel PI3K ...... ritis in Pre-Clinical Studies.
@ast
Characterization of Novel PI3K ...... ritis in Pre-Clinical Studies.
@en
type
label
Characterization of Novel PI3K ...... ritis in Pre-Clinical Studies.
@ast
Characterization of Novel PI3K ...... ritis in Pre-Clinical Studies.
@en
prefLabel
Characterization of Novel PI3K ...... ritis in Pre-Clinical Studies.
@ast
Characterization of Novel PI3K ...... ritis in Pre-Clinical Studies.
@en
P2093
P2860
P356
P1476
Characterization of Novel PI3K ...... hritis in Pre-Clinical Studies
@en
P2093
Audrey Benoit
Carole Jond-Necand
Caroline Waltzinger
Catherine Martin
Christoph Ladel
Denise Gretener
Dominique Bertschy Meier
Jørgen Søberg Petersen
Lisa Bruns
P2860
P356
10.3389/FIMMU.2014.00233
P577
2014-05-22T00:00:00Z